The Chronic Liver Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Liver Disease. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Liver Disease and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Chronic Liver Disease by 14 companies/universities/institutes. The top development phase for Chronic Liver Disease is discovery with seven drugs in that stage. The Chronic Liver Disease pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chronic Liver Disease pipeline products market are: HepaRegeniX, LinXis and PrimeGen Global.

The key targets in the Chronic Liver Disease pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 4 (JNK Activating Kinase 1 or MAPK/ERK Kinase 4 or SAPK/ERK Kinase 1 or Stress Activated Protein Kinase Kinase 1 or c Jun N Terminal Kinase Kinase 1 or MEK4 or MAP2K4 or EC 2.7.12.2), Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1), and High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1).

The key mechanisms of action in the Chronic Liver Disease pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 4 (JNK Activating Kinase 1 or MAPK/ERK Kinase 4 or SAPK/ERK Kinase 1 or Stress Activated Protein Kinase Kinase 1 or c Jun N Terminal Kinase Kinase 1 or MEK4 or MAP2K4 or EC 2.7.12.2) Inhibitor with two drugs in Phase I. The Chronic Liver Disease pipeline products include three routes of administration with the top ROA being Oral and five key molecule types in the Chronic Liver Disease pipeline products market including Small Molecule, and Cell Therapy.

Chronic Liver Disease overview

Chronic liver disease is a progressive decline in liver functions, encompassing crucial roles such as clotting factor and protein production, detoxification, and bile excretion. It involves a continual cycle of inflammation, destruction, and regeneration of liver parenchyma, culminating in fibrosis and cirrhosis. Cirrhosis, the advanced stage, disrupts liver architecture, creating nodules, reorganizing vasculature, inducing neo-angiogenesis, and depositing extracellular matrix. The cellular mechanism involves stellate cell and fibroblast recruitment, leading to fibrosis, while hepatic stem cells play a pivotal role in parenchymal regeneration. Understanding this complex process is essential for effective management of chronic liver diseases.

For a complete picture of Chronic Liver Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.